The agency also granted traditional approval to later-line nivolumab indications for certain adults with the disease.
The FDA has approved the combination of nivolumab plus chemotherapy as first-line treatment for certain patients with stage III or IV classical Hodgkin lymphoma.The approval, for individuals aged 12 ...
FDA approval extends nivolumab into first-line stage III/IV cHL in adults and pediatrics, following priority review of the supplemental application for nivolumab plus AVD. SWOG S1826 showed superior ...
Frontline nivolumab plus AVD reduced risk of progression or death by 58% versus brentuximab vedotin plus AVD (PFS HR, 0.42) in advanced-stage classical Hodgkin lymphoma. CA209-8UT randomized 994 ...
Taking GLP-1 drugs for diabetes has been shown to lower the risk of adverse heart events, but a new analysis found that going off the medication – even for a few months – may increase the odds of ...
Research finds that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in ...
A major study links Wegovy to a rare form of sudden vision loss, and finds men may face three times the risk of women.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results